has sponsored live events, journal education, and internet-based CME activities and has awarded more than 80,000 hours of CME credit.Early View from The Oncologist
- Regarding “HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer”
- PARP Inhibitors & Prostate Cancer: To Infinity and Beyond BRCA
- Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer
- Weekly Carboplatin and Paclitaxel: A Retrospective Comparison with the Three‐Weekly Schedule in First‐Line Treatment of Ovarian Cancer
- Pre‐treatment blood parameters predict efficacy from immunotherapy agents in early phase clinical trials
- Clinical Characteristics and Mutation Analyses of Ovarian Sertoli‐Leydig Cell Tumors
- Erlotinib for Non‐Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101)
- KEYNOTE‐032: A Randomized Phase I Study of Pembrolizumab in Chinese Patients with Advanced Non‐Small Cell Lung Cancer
- Immune‐Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration‐Approved Indications for Immunotherapy
- Cardiovascular Outcomes in Relation to Antihypertensive Medication Use in Women with and Without Cancer: Results from the Women's Health Initiative